Quadrivalent meningococcal vaccines: Hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine

Travel Medicine and Infectious Disease

Volumn 8, Issue 1, 2010, Pages 47-50

  Bröker, Michael ^a   Veitch, Keith ^a  

^a Novartis Vaccines and Diagnostics GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MENAFRIVAC; MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MENINGOCOCCOSIS; MORBIDITY; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; PUBLIC HEALTH; SERUM BACTERICIDAL ACTIVITY; TRAVEL;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION, SECONDARY; INFANT; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; SEROTYPING; VACCINES, CONJUGATE;

EID: 76949097477     PISSN: 14778939     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmaid.2009.12.001     Document Type: Article

References (25)

1. Ericson L., and De Wals P. Complication and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis 26 (1998) 1159-1164
2. Harrison L.H., Trotter C.L., and Ramsey M.E. Global epidemiology of meningococcal disease. Vaccine 27 Suppl. 2 (2009) B51-B63
3. LaForce F.M., Ravenscroft N., Djingarey M., and Viviani S. Epidemic meningitis due to group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 27 Suppl. 2 (2009) B13-B19
4. Wilder-Smith A. Meningococcal disease: risk for international travellers and vaccine strategies. Travel Med Infect Dis 6 (2008) 182-186
5. Harrison I.H. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 19 (2006) 142-164
6. Pace D., Pollard A.J., and Messonier N.E. Quadrivalent meningococcal conjugate vaccines. Vaccine 275 (2009) 830-841
7. Østergaard L., Lebacq E., Poolman J., Maechler G., and Boutriau D. Imunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 27 (2009) 161-168
8. Granoff D.M., and Pollard A.J. Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr Infect Dis J 26 (2007) 716-722
9. Keyserling H., Papa T., Koranyi K., et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 159 (2005) 907-913
10. Gold R., Lepow M.L., Goldschneider I., Draper T.L., and Gotschlich E.C. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest 56 (1975) 1536-1547
11. MacDonald N., Halperin S.A., Law B.J., Forrest B., Danzig L.E., and Granoff D.M. Induction of immunological memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers. J Am Assoc Am 280 (1998) 1685-1689
12. Richmond P., Kaczmarski E., Borrow R., et al. Meningococcal C polysaccharide vaccine induces hyporesponsiveness in adults that is overcome by conjugate vaccine. J Infect Dis 181 (2000) 761-764
13. Southern J., Deane S., Ashton L., et al. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin Diagn Lab Immunol 11 (2004) 1100-1104
14. MacDonald N.E., Halperin S.A., Law B.J., Danzig L.E., and Granoff D.M. Can meningococcal C conjugate vaccine overcome immune hyporesponsiveness induced by previous administration of plain polysaccharide vaccine?. J Am Med Assoc 283 (2000) 1826-1827
15. Trotter C.L., McVernon J., and Ramsey M.E. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine 26 (2008) 4434-4445
16. Bröker M. Vaccination against meningococcal disease: which vaccine to use?. J Travel Med 9 (2002) 168-169
17. MacLennan J., Obaro S., Deeks J., et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine 17 (1999) 3086-3093
18. Borrow R., Joseph H., Andrews N., et al. Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults. Vaccine 19 (2001) 1129-1132
19. Jokhdar H., Borrow R., Sultan A., et al. Immunologic hyporesponsiveness to serogroup C but not to serogroup A following repeated meningococcal A/C polysaccharide vaccination in Saudi Arabia. Clin Diagn Lab Imunol 11 (2004) 83-88
20. Gold R., Lepow M.L., Goldschneider I., Draper T., and Gotschlich E.C. Kinetics of antibody production to group A an group C meningococcal polysaccharide vaccine administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis 140 (1979) 690-697
21. Käyhty H., Karanko V., Peltola H., Sarna S., and Mäkelä H. Serum antibodies to capsular polysaccharide vaccine of group A Neisseria meningitidis followed for three years in infants and children. J Clin Infect Dis 142 (1980) 861-868
22. Nathan N., Rose A.M.C., Legros D., et al. Meningitis serogroup W135 outbreak, Burkina Faso, 2002. Emerg Infect Dis 13 (2007) 920-923
23. Al Mazrou Y., Khalil M., Borrow R., et al. Serologic response to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age. Infect Immun 73 (2005) 2932-2939
24. Al-Mazriou Y, Khalil M, Bravo C et al. Meningococcal conjugate vs meningococal polysaccharide vaccine in Saudi Arabian adolescents previously vaccinated with multiple doses of meningococcal polysaccharide vaccine. Abstract O002. 10th Meeting of the European Monitoring Group for Meningococci (EMGM), Manchester, UK, June 17-19, 2009.
25. Khalil M, Al-Mazrou Y, Bravo C et al. Response to quadrivalent meningococcal conjugate vaccine in Saudi Arabian children who previously received 2 doses of quadrivalent meningococcal polysaccharide vaccine before 1 years of age. Abstract P008. 10th Meeting of the European Monitoring Group for Meningococci (EMGM), Manchester, UK, June 17-19, 2009.